I dont have any real comment to make - other than .....things dont always go to plan & there are no guarantees in the biotec space - or any public company space for that matter .
However , its really well worth reading the last dozen or so announcements & news letters etc that IMU have released .
Yes - sounds like a really great team on board & very credible
Yes - sounds like they are onto something quite different , but with some good early proof of concept .
Yes - they are classed as a player an " Imuno Oncology " ........ space - a very "in" space right now . ( a bit like block chain & Lithium ) ...... and a lot of people probably put them in the same space as the other players .
Its this difference ( see below ) ............that seems to set them apart .
However........ - "Instead Imugene is looking at a new B cell delivery platform which should replace for example the old T-cell PD-1 with Imugenes new B cell polyclonal PD-1 instead
Read up ....... worth the effort I think
,
No guarantees - but geez if they pull it off ...... 3 cents could go to $3.00
In my book thats worth a decent crack !!!
Its really a matter of how many shares you can afford & how much its going to kill you if they dont pull it off .
The risk reward scenrio is quite good
For me in any event
cheers
VA
Add to My Watchlist
What is My Watchlist?
